These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11120391)

  • 1. The neurobehavioral effects of subchronic manganese exposure in the presence and absence of pre-parkinsonism.
    Witholt R; Gwiazda RH; Smith DR
    Neurotoxicol Teratol; 2000; 22(6):851-61. PubMed ID: 11120391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low cumulative manganese exposure affects striatal GABA but not dopamine.
    Gwiazda RH; Lee D; Sheridan J; Smith DR
    Neurotoxicology; 2002 May; 23(1):69-76. PubMed ID: 12164549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
    Meshul CK; Kamel D; Moore C; Kay TS; Krentz L
    Exp Neurol; 2002 May; 175(1):257-74. PubMed ID: 12009777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of bioaccumulation, neuropathology, and neurobehavior following subchronic (90 days) inhalation in Sprague-Dawley rats exposed to manganese phosphate.
    Normandin L; Carrier G; Gardiner PF; Kennedy G; Hazell AS; Mergler D; Butterworth RF; Philippe S; Zayed J
    Toxicol Appl Pharmacol; 2002 Sep; 183(2):135-45. PubMed ID: 12387753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
    Senthilkumar KS; Saravanan KS; Chandra G; Sindhu KM; Jayakrishnan A; Mohanakumar KP
    Behav Brain Res; 2007 Nov; 184(1):11-8. PubMed ID: 17765334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
    Cohen AD; Tillerson JL; Smith AD; Schallert T; Zigmond MJ
    J Neurochem; 2003 Apr; 85(2):299-305. PubMed ID: 12675906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?
    Kim Y; Kim JM; Kim JW; Yoo CI; Lee CR; Lee JH; Kim HK; Yang SO; Chung HK; Lee DS; Jeon B
    Mov Disord; 2002 May; 17(3):568-75. PubMed ID: 12112209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
    Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
    Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments.
    Szkilnik R; Brus R; Malinowska-Borowska J; Nowak D; Waliczek M; Kostrzewa RM; Nowak P
    Environ Toxicol Pharmacol; 2014 Jan; 37(1):28-36. PubMed ID: 24295730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
    Xue YQ; Zhao LR; Guo WP; Duan WM
    Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of manganese-associated neurotoxicity.
    Racette BA; Aschner M; Guilarte TR; Dydak U; Criswell SR; Zheng W
    Neurotoxicology; 2012 Aug; 33(4):881-6. PubMed ID: 22202748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats.
    Chen L; Deltheil T; Turle-Lorenzo N; Liberge M; Rosier C; Watabe I; Sreng L; Amalric M; Mourre C
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1295-306. PubMed ID: 24661728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
    Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F
    Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions.
    van Dijk A; Johnston C; Allbutt H; Kassiou M; Henderson J
    Behav Brain Res; 2008 Jun; 190(1):14-21. PubMed ID: 18378329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson's disease in rats.
    Hegazy MA; Maklad HM; Samy DM; Abdelmonsif DA; El Sabaa BM; Elnozahy FY
    Neurochem Int; 2017 Sep; 108():361-371. PubMed ID: 28527632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
    Oiwa Y; Sanchez-Pernaute R; Harvey-White J; Bankiewicz KS
    J Neurosurg; 2003 Jan; 98(1):136-44. PubMed ID: 12546362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor.
    Díaz-Véliz G; Mora S; Gómez P; Dossi MT; Montiel J; Arriagada C; Aboitiz F; Segura-Aguilar J
    Pharmacol Biochem Behav; 2004 Feb; 77(2):245-51. PubMed ID: 14751451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
    Van Keuren KR; Stodgell CJ; Schroeder SR; Tessel RE
    Brain Res; 1998 Jan; 780(1):56-66. PubMed ID: 9473587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.